Table 1 Patient characteristics

Sex

0.254

Male

80 (79.2%)

73 (71.6%)

Female

21 (20.8%)

29 (28.4%)

Age

Median (IQR, years)

57 (50–65)

61 (51-67.25)

0.151

< 60 years

59 (58.4%)

49 (48%)

0.16

BMI

Median (IQR, kg/m²)

21.64 (20.24–24.22)

22.15 (20.48–24.22)

0.637

Smoking

59 (58.4%)

60 (58.8%)

1

Drinking

53 (52.5%)

59 (57.8%)

0.482

Comorbidity

Hypertension

14 (13.9%)

16 (15.7%)

0.844

Coronary heart disease

3 (3%)

4 (3.9%)

1

Diabetes

14 (13.9%)

8 (7.8%)

0.183

Other

15 (14.9%)

12 (11.8%)

0.542

Family history

4 (4%)

7 (6.9%)

0.537^f

ASA

0.622

1

2 (2%)

1 (1%)

2

63 (62.4%)

56 (54.9%)

3

35 (34.6%)

44 (43.1%)

4

1 (1%)

1(1%)

Pretreatment Hb (IQR, g/L)

118 (86–133)

125 (92–139)

0.17

Pretreatment neutrophils (IQR, *10⁸)

3.74 (3.09–4.76)

3.72 (2.92–4.92)

0.969

Pretreatment lymphocyte (IQR, *10⁸)

1.37 (1.06–1.68)

1.41 (1.13–1.73)

0.574

Pretreatment platelet (IQR, *10⁸)

243 (203–351)

235 (181–307)

0.235

Pretreatment albumin (IQR, g/L)

38 (34–41)

31 (33–40)

0.567

Pretreatment CEA(>5.2 ng/ml)

36 (35.6%)

26 (25.5%)

0.129

Pretreatment CA19-9 (> 27 U/ml)

34 (33.7%)

29 (28.4%)

0.451

Tumor location

0.766

Upper stomach

35 (34.6%)

36 (35.3%)

Middle stomach

22 (21.8%)

26 (25.5%)

Lower stomach

44 (43.6%)

40 (39.2%)

Tumor size (IQR, cm)

6 (5-7.7)

5.57 (4.6–6.8)

0.236

Borrmann typing

0.49

I

26 (25.7%)

34 (33.3%)

II

12 (11.9%)

12 (11.8%)

III

51 (34.6%)

49 (48%)

IV

12 (11.9%)

7 (6.9%)

Clinical T stage

0.859

T3

24 (23.8%)

27 (26.5%)

T4a

70 (69.3%)

67 (65.7%)

T4b

7 (6.9%)

8 (7.8%)

Clinical N stage

0.374

N0

11 (10.9%)

17 (16.7%)

N1

29 (28.7%)

27 (26.5%)

N2

42 (41.6%)

46 (45.1%)

N3

19 (18.8%)

12 (11.8%)

Clinical TNM stage

0.825

IIa

2 (2%)

3 (2.9%)

IIb

16 (15.8%)

22 (21.6%)

IIIa

31 (30.7%)

30 (29.4%)

IIIb

35 (34.7%)

33 (32.4%)

IIIc

17 (16.8%)

14 (13.7%)

Chemotherapy regimen

0.152

NPOS

56 (55.4%)

67 (65.7%)

DOS

45 (44.6%)

35 (34.3%)

Number of neoadjuvant therapy cycles

0.175

2

49 (48.5%)

57 (55.9%)

3

40 (39.6%)

40 (39.2%)

4

12 (11.9%)

5(4.9%)

Number of chemoembolization

1

91 (89.2%)

2

11(10.8%)